Biointercept is at the forefront of oncology and hematology research, leveraging cutting-edge technologies to
revolutionize cancer treatment and blood disorder management. Our scientists employ advanced techniques with our proprietary exosome technology
to help solve oncologies most challenging problems.
By integrating multi-omics data with sophisticated bioinformatics, we are uncovering
crucial insights into cancer progression, drug resistance mechanisms, and personalized treatment strategies, paving the
way for more effective and less toxic interventions.
Cancer remains a leading cause of death globally, with the oncology therapeutics market
exceeding $150 billion annually. Exosomes present a dual opportunity in oncology spanning
both therapeutic and diagnostic applications.
This therapeutic platform demonstrates significantly enhanced penetration into solid tumors, outperforming conventional antibodies and nanoparticlses. Crucially, it possesses the unique ability to cross the blood-brain barrier, opening new avenues for effective brain tumor treatment. This precise targeting capability leads to substantially reduced off-target toxicity compared to conventional chemotherapy, improving patient safety. The platform's high degree of specificity is achieved by engineering exosome surface proteins. This versatility allows for multiple, simultaneous targeting strategies to be deployed. Ultimately, these combined attributes create a more potent and safer approach to treating historically challenging diseases.